来自 33 只狗（25 只皮下和 8 只关节）的肉瘤样本被提交用于细胞角蛋白免疫组织化学分析。 25 个皮下肉瘤中有 8 个 (32%) 在 1% 至 50% 的肿瘤细胞中表达细胞角蛋白。在评估的 7 种关节肉瘤中，1 种（14%）在 10% 的肿瘤细胞中表达细胞角蛋白。 Kaplan-Meier 生存分析显示，皮下肉瘤犬的平均总生存期（28.1 个月 [置信区间 [CI]:17.8, 38.4]）与关节肉瘤犬的平均总生存期（24.8 个月 [CI = 0.5, 29.0]）没有显着差异。 ]）。细胞角蛋白免疫反应性肉瘤（两个部位合并）狗的总生存期（31.2个月[CI = 17.8, 44.6]）与细胞角蛋白无免疫反应性肉瘤狗的总生存期（22.0个月[CI = 8.4, 35.6]）没有差异。因此，在这项小型研究中，细胞角蛋白表达并不表明滑膜起源（P = .64），肉瘤位置（P = .76）和细胞角蛋白表达（P = .53）都不影响患者的总体生存率。使用细胞角蛋白免疫组织化学无助于确定狗肉瘤的滑膜起源。

Sarcoma samples from 33 dogs, 25 subcutaneous and 8 articular, were submitted for cytokeratin immunohistochemistry. Eight of the 25 subcutaneous sarcomas (32%) expressed cytokeratin in 1% to 50% of the neoplastic cells. Of the 7 articular sarcomas evaluated, 1 (14%) expressed cytokeratin in 10% of neoplastic cells. The Kaplan-Meier survival analysis showed that the mean overall survival of dogs with subcutaneous sarcomas (28.1 months [confidence interval [CI]:17.8, 38.4]) did not significantly differ from those with articular sarcomas (24.8 months [CI = 0.5, 29.0]). Overall survival of dogs with sarcomas (both locations combined) immunoreactive for cytokeratin (31.2 months [CI = 17.8, 44.6]) did not differ from those not immunoreactive for cytokeratin (22.0 months [CI = 8.4, 35.6]). Therefore, cytokeratin expression does not indicate synovial origin (P = .64) and neither sarcoma location (P = .76) nor cytokeratin expression (P = .53) affects patient overall survival in this small study. The use of cytokeratin immunohistochemistry is not helpful to determine synovial origin of sarcomas in dogs.